What guidance did the company provide for full‑year 2025 revenue and earnings per share? | PLSE (Aug 12, 2025) | Candlesense
PLSE

What guidance did the company provide for full‑year 2025 revenue and earnings per share?

Guidance Summary

In the second‑quarter 2025 release, Pulse Biosciences did not disclose explicit full‑year 2025 revenue or earnings‑per‑share (EPS) figures. The press release focuses on business updates—such as the expansion of the soft‑tissue ablation pilot program and the treatment of >140 benign thyroid‑nodule patients—but it omits the specific revenue and EPS guidance that investors typically look for in a full‑year outlook.

Trading Implications

Because the company left full‑year revenue and EPS guidance out of the release, the market is likely pricing in the company’s recent operational progress rather than concrete financial forecasts. Traders should watch for a supplemental “full‑year guidance” release or an earnings call transcript where the numbers might be disclosed. In the meantime, the stock’s near‑term direction will be driven more by technical momentum (e.g., price action around the Q2 earnings beat or miss, relative volume, and short‑interest data) and fundamental catalysts (e.g., further expansion of the nsPFA platform, regulatory milestones, and additional pilot‑program data). Until the company publishes definitive full‑year numbers, any trades based on earnings expectations remain speculative, and risk‑adjusted positioning—such as a small‑cap, high‑volatility play with tight stops—may be prudent.

Other Questions About This News

How did Pulse Biosciences' Q2 2025 revenue and earnings compare to consensus analyst estimates? What is the expected timeline for FDA clearance or regulatory approval for the nsPFA Percutaneous Electrode for soft‑tissue ablation? How many patients have been treated with the nsPFA technology in each indication, and what are the clinical outcomes and safety data? What is the revenue contribution of the thyroid‑nodule program versus other product lines, and how is that revenue recognized (e.g., product sales, collaborations, grant funding)? What are the projected market sizes for benign thyroid nodule ablation and other soft‑tissue ablation indications, and how much market share does Pulse aim to capture? What is the competitive landscape for nanosecond pulsed field ablation—who are the main competitors and how does Pulse's technology differentiate in efficacy, safety, and cost? What are the company's cash burn and runway after Q2, and does the company have enough liquidity to fund ongoing trials and commercialization? Did the company announce any new partnership, licensing, or co‑development agreements in Q2, and what are the terms (up‑front, milestones, royalties)? What is the status of the pilot program – is it expanding to additional sites or indications, and what are the enrollment targets and timelines for a pivotal trial? What risk factors were highlighted in the earnings release (e.g., regulatory risk, technology adoption risk, reimbursement uncertainty) that could affect the valuation? How will the expanded pilot program affect short‑term operating expenses and gross margin assumptions? What is the anticipated impact on the share price in the near term, given the sentiment score of 60 and the market's reaction to previous earnings releases? Are there any upcoming catalyst events (e.g., data readouts, regulatory submissions, investor presentations) that could drive volatility in PLSE stock?